Population-based case control study of the safety of sulfasalazine use during pregnancy

B. Nørgård, E. Czeizel, M. Rockenbauer, J. Olsen, H. T. Sørensen

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: We studied the human teratogenic risk of sulfasalazine because this drug interferes with folate metabolism. Methods: Case control study within the Hungarian Case Control Surveillance of Congenital Abnormalities, 1980-1996; based on 22 865 new-born infants or foetuses with congenital abnormalities, and 38 151 babies without any detected congenital abnormalities (control group). Results: Seventeen pregnant women (0.07%) were treated with sulfasalazine in the case group, and 26 (0.07%) in the control group. The overall adjusted adds ratio of congenital abnormalities after sulfasalazine treatment was odds ratio = 1.2 (95% confidence interval: 0.6-2.1). None of the analyses indicated any significant increased prevalence of selected congenital abnormalities among the exposed compared with the not exposed. Conclusions: We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy. However, the amount of information is limited and additional data are needed to rule out a teratogenic effect.

Original languageEnglish
Pages (from-to)483-486
Number of pages4
JournalAlimentary Pharmacology and Therapeutics
Volume15
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Sulfasalazine
Case-Control Studies
Safety
Pregnancy
Population
Control Groups
Folic Acid
Pregnant Women
Fetus
Odds Ratio
Confidence Intervals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Population-based case control study of the safety of sulfasalazine use during pregnancy. / Nørgård, B.; Czeizel, E.; Rockenbauer, M.; Olsen, J.; Sørensen, H. T.

In: Alimentary Pharmacology and Therapeutics, Vol. 15, No. 4, 2001, p. 483-486.

Research output: Contribution to journalArticle

@article{7837d800c25b4048b0c31206addf55fb,
title = "Population-based case control study of the safety of sulfasalazine use during pregnancy",
abstract = "Background: We studied the human teratogenic risk of sulfasalazine because this drug interferes with folate metabolism. Methods: Case control study within the Hungarian Case Control Surveillance of Congenital Abnormalities, 1980-1996; based on 22 865 new-born infants or foetuses with congenital abnormalities, and 38 151 babies without any detected congenital abnormalities (control group). Results: Seventeen pregnant women (0.07{\%}) were treated with sulfasalazine in the case group, and 26 (0.07{\%}) in the control group. The overall adjusted adds ratio of congenital abnormalities after sulfasalazine treatment was odds ratio = 1.2 (95{\%} confidence interval: 0.6-2.1). None of the analyses indicated any significant increased prevalence of selected congenital abnormalities among the exposed compared with the not exposed. Conclusions: We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy. However, the amount of information is limited and additional data are needed to rule out a teratogenic effect.",
author = "B. N{\o}rg{\aa}rd and E. Czeizel and M. Rockenbauer and J. Olsen and S{\o}rensen, {H. T.}",
year = "2001",
doi = "10.1046/j.1365-2036.2001.00962.x",
language = "English",
volume = "15",
pages = "483--486",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Population-based case control study of the safety of sulfasalazine use during pregnancy

AU - Nørgård, B.

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Olsen, J.

AU - Sørensen, H. T.

PY - 2001

Y1 - 2001

N2 - Background: We studied the human teratogenic risk of sulfasalazine because this drug interferes with folate metabolism. Methods: Case control study within the Hungarian Case Control Surveillance of Congenital Abnormalities, 1980-1996; based on 22 865 new-born infants or foetuses with congenital abnormalities, and 38 151 babies without any detected congenital abnormalities (control group). Results: Seventeen pregnant women (0.07%) were treated with sulfasalazine in the case group, and 26 (0.07%) in the control group. The overall adjusted adds ratio of congenital abnormalities after sulfasalazine treatment was odds ratio = 1.2 (95% confidence interval: 0.6-2.1). None of the analyses indicated any significant increased prevalence of selected congenital abnormalities among the exposed compared with the not exposed. Conclusions: We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy. However, the amount of information is limited and additional data are needed to rule out a teratogenic effect.

AB - Background: We studied the human teratogenic risk of sulfasalazine because this drug interferes with folate metabolism. Methods: Case control study within the Hungarian Case Control Surveillance of Congenital Abnormalities, 1980-1996; based on 22 865 new-born infants or foetuses with congenital abnormalities, and 38 151 babies without any detected congenital abnormalities (control group). Results: Seventeen pregnant women (0.07%) were treated with sulfasalazine in the case group, and 26 (0.07%) in the control group. The overall adjusted adds ratio of congenital abnormalities after sulfasalazine treatment was odds ratio = 1.2 (95% confidence interval: 0.6-2.1). None of the analyses indicated any significant increased prevalence of selected congenital abnormalities among the exposed compared with the not exposed. Conclusions: We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy. However, the amount of information is limited and additional data are needed to rule out a teratogenic effect.

UR - http://www.scopus.com/inward/record.url?scp=0035075860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035075860&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2001.00962.x

DO - 10.1046/j.1365-2036.2001.00962.x

M3 - Article

C2 - 11284776

AN - SCOPUS:0035075860

VL - 15

SP - 483

EP - 486

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -